Noticia

La Iniciativa de Medicamentos Innovadores IMI2 abrió el pasado 30 de noviembre la 13ª convocatoria formada por los 13 topics siguientes:

• Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches


• Genome-environment interactions in inflammatory skin disease


• The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use


• Mitochondrial dysfunction in neurodegeneration


• Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative


• A sustainable European induced pluripotent stem cell platform


• Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice


• Human tumour microenvironment immunoprofiling


• ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now


• Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system


• Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease


• Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases

Son propuestas a evaluar en 2 fases, siendo el plazo de cierre de la 1ª fase el 28 de febrero de 2018 a las 17.00 h (hora de Bruselas). El presupuesto para esta convocatoria es de 223.053.000 Euros.

Más información en el siguiente enlace: IMI launches new calls for proposals